2025-00425. Mandatory Guidelines for Federal Workplace Drug Testing Programs-Authorized Testing Panels

Report Nomenclature—Urine

Urine
Abbreviation	Analyte
Δ9THCC	Δ-9-tetrahydrocannabinol-9-carboxylic acid.
BZE	Benzoylecgonine.
COD	Codeine.
MOR	Morphine.
HYC	Hydrocodone.
HYM	Hydromorphone.
OXYC	Oxycodone.
OXYM	Oxymorphone.
6-AM	6-Acetylmorphine.
PCP	Phencyclidine.
FENT	Fentanyl.
NFENT	Norfentanyl.
AMP	Amphetamine.
MAMP	Methamphetamine.
MDMA	Methylenedioxymethamphetamine.
MDA	Methylenedioxyamphetamine.

HHS Drug Testing Panel—Urine

Initial test analyte	Initial test cutoff 1	Confirmatory test analyte	Confirmatory test cutoff
Marijuana metabolite (Δ9THCC)	50 ng/mL.	Δ9THCC	15 ng/mL.
Cocaine metabolite (Benzoylecgonine)	150 ng/mL.2	Benzoylecgonine	100 ng/mL.
Codeine/Morphine	2,000 ng/mL.	Codeine Morphine	2,000 ng/mL. 4,000 ng/mL.
Hydrocodone/Hydromorphone	300 ng/mL.	Hydrocodone Hydromorphone	100 ng/mL. 100 ng/mL.
Oxycodone/Oxymorphone	100 ng/mL.	Oxycodone Oxymorphone	100 ng/mL. 100 ng/mL.
6-Acetylmorphine	10 ng/mL.	6-Acetylmorphine	10 ng/mL.
Phencyclidine	25 ng/mL.	Phencyclidine	25 ng/mL.
Fentanyl 3	1 ng/mL.	Fentanyl Norfentanyl	1 ng/mL. 1 ng/mL.
Amphetamine/Methamphetamine	500 ng/mL.	Amphetamine Methamphetamine	250 ng/mL. 250 ng/mL.
MDMA/MDA	500 ng/mL.	Methylenedioxymethamphetamine Methylenedioxyamphetamine	250 ng/mL. 250 ng/mL.
1   For grouped analytes ( i.e., two or more analytes that are in the same drug class and have the same initial test cutoff):
Immunoassay: The test must be calibrated with one analyte from the group identified as the target analyte. The cross-reactivity of the immunoassay to the other analyte(s) within the group must be 80 percent or greater; if not, separate immunoassays must be used for the analytes within the group. ( print page 4668)
Alternate technology: Either one analyte or all analytes from the group must be used for calibration, depending on the technology. For a technology that measures a response from the entire group without differentiating between analytes ( e.g., an activity-based assay, a mass spectrometric assay that does not differentiate isobaric compounds), the laboratory must compare the result to the initial test cutoff. In the case of an alternate technology that differentiates and quantifies each analyte in the group, the laboratory must compare each analyte's result to the confirmatory test cutoff and reflex specimens with a positive initial test result to confirmatory testing.
2   Alternate technology (BZE): The confirmatory test cutoff must be used for an alternate technology initial test that is specific for the target analyte ( i.e., 100 ng/mL for benzoylecgonine).
3  A fentanyl immunoassay must have at least 5% cross-reactivity to norfentanyl.

HHS Biomarker Testing Panel—Urine

SAMHSA has not yet authorized routine testing for any biomarker in urine. HHS-certified laboratories and instrumented initial test facilities (IITFs) may request authorization to test Federal agency specimens for a biomarker upon Medical Review Officer (MRO) request by submitting supporting documentation and assay validation records to the National Laboratory Certification Program (NLCP) for SAMHSA review and approval.

Report Nomenclature—Oral Fluid

Oral fluid
Abbreviation	Analyte
Δ9THC	Δ-9-tetrahydrocannabinol.
COC	Cocaine.
BZE	Benzoylecgonine.
COD	Codeine.
MOR	Morphine.
HYC	Hydrocodone.
HYM	Hydromorphone.
OXYC	Oxycodone.
OXYM	Oxymorphone.
6-AM	6-Acetylmorphine.
PCP	Phencyclidine.
FENT	Fentanyl.
AMP	Amphetamine.
MAMP	Methamphetamine.
MDMA	Methylenedioxymethamphetamine.
MDA	Methylenedioxyamphetamine.

HHS Drug Testing Panel—Oral Fluid

HHS drug testing panel—undiluted (neat) oral fluid
Initial test analyte	Initial test cutoff 1	Confirmatory test analyte	Confirmatory test cutoff
Marijuana (Δ9THC)	4 ng/mL.	Δ9THC	2 ng/mL.
Cocaine/Benzoylecgonine	15 ng/mL.	Cocaine Benzoylecgonine	8 ng/mL. 8 ng/mL.
Codeine/Morphine	30 ng/mL.	Codeine Morphine	15 ng/mL. 15 ng/mL.
Hydrocodone/Hydromorphone	30 ng/mL.	Hydrocodone Hydromorphone	15 ng/mL. 15 ng/mL.
Oxycodone/Oxymorphone	30 ng/mL.	Oxycodone Oxymorphone	15 ng/mL. 15 ng/mL.
6-Acetylmorphine	4 ng/mL.2	6-Acetylmorphine	2 ng/mL.
Phencyclidine	10 ng/mL.	Phencyclidine	10 ng/mL.
Fentanyl	4 ng/mL.	Fentanyl	1 ng/mL.
Amphetamine/Methamphetamine	50 ng/mL.	Amphetamine Methamphetamine	25 ng/mL. 25 ng/mL.
MDMA/MDA	50 ng/mL.	Methylenedioxymethamphetamine Methylenedioxyamphetamine	25 ng/mL. 25 ng/mL.
1   For grouped analytes ( i.e., two or more analytes that are in the same drug class and have the same initial test cutoff):
Immunoassay: The test must be calibrated with one analyte from the group identified as the target analyte. The cross reactivity of the immunoassay to the other analyte(s) within the group must be 80 percent or greater; if not, separate immunoassays must be used for the analytes within the group.
Alternate technology: Either one analyte or all analytes from the group must be used for calibration, depending on the technology. For a technology that measures a response from the entire group without differentiating between analytes (e.g., an activity-based assay, a mass spectrometric assay that does not differentiate isobaric compounds), the laboratory must compare the result to the initial test cutoff. In the case of an alternate technology that differentiates and quantifies each analyte in the group, the laboratory must compare each analyte's result to the confirmatory test cutoff and reflex specimens with a positive initial test result to confirmatory testing.
2   Alternate technology (6-AM): The confirmatory test cutoff must be used for an alternate technology initial test that is specific for the target analyte ( i.e., 2 ng/mL for 6-AM).